Ponatinib is a multi-targeted kinase inhibitor and is currently the only approved TKI active against the T315I BCR-ABL kinase domain mutation (see below; O’Hare et al., 2009), and therefore is an important treatment modality in BCR::ABL1-positive leukaemias. This evidence concerns the gene BCR and leukemia.